Jonathan Granek

Founding Director, EHE Rare Cancer Foundation Australia | Member, PeterMac Community Advisory Committee | Consumer Rep, PeterMac | Consumer Rep, WEHI

[EHE Foundation @EHEfoundation]

Encouraging results presented at ASCO!

Read Orion's press release here: https://t.co/MWbzMTpEDL

[EHE Foundation @EHEfoundation]

Be in the room for one of the most valuable conversations of EHE 360. The popular 'Ask the Expert' Panel! These trusted EHE experts are taking time to address the questions that matter most. ❤️🙋

https://t.co/FKipBstVSv

📅 Thursday, 4/30 - Friday, 5/1
⏰ 10am ET - 1pm ET

[EHE Foundation @EHEfoundation]

✨ View agenda and register: https://t.co/FKipBstVSv

Join us live at EHE 360! In a rare cancer like EHE, progress depends on collaboration, and this session will highlight the partnerships helping accelerate discovery.

📅 Thursday, 4/30 - Friday, 5/1
⏰ 10am ET - 1pm ET

[EHE Foundation @EHEfoundation]

If you want the latest #ClinicalTrial updates directly from the experts leading this work, this EHE 360 session is one to attend live! 🔬🎗️🩺🧬

Explore the full agenda and register: https://t.co/FKipBstVSv

📅 Thursday, April 30 - Friday, May 1, 2026
⏰ 10am ET - 1pm ET

[EHE Foundation @EHEfoundation]

Happening this week!!!

Join us LIVE to hear from the experts helping improve outcomes for people with EHE at EHE 360. View full agenda and register here: https://t.co/FKipBstVSv

📅 Thursday, 4/30 - Friday, 5/1
⏰ 10am ET - 1pm ET

[EHE Foundation @EHEfoundation]

New to EHE 360 this year: SOCIAL HOUR immediately following Friday’s presentations! 💻

Join us for this free virtual conference dedicated entirely to EHE — and be part of the conversations helping move progress forward.

View the full agenda and register: https://t.co/FKipBstVSv

[Liz Connolly @DrLizConnolly]

‼️ There are many unanswered questions, unmet needs & work to be done👇

A global expert consensus meeting 🌍 is being planned to help address these needs

✋Please get in touch if you work or research in this space & would like to be involved

4/4

@CMRI_AUS @COBLH @PeterMacCC

[EHE Foundation @EHEfoundation]

👉 The EHE 360 Global Patient Conference begins TODAY. Register for this free and virtual event at the link below. Don't miss this opportunity to empower and inform your EHE journey! Registration is required.

https://t.co/ixbyYKN1Ci

#EHE360 #epithelioidhemangioendothelioma

[Omico Australia @OmicoAustralia]

A new research initiative is set to change the landscape of sarcoma treatment. Through the MoST / CaSP SARC Research Project, Omico—together with Cooper Rice-Brading Foundation (CRBF), the Tom Hardyman Sarcoma Research Fund, and Tour de Cure Australia on behalf of the Andrew Dreverman Legacy for Sarcoma Research Fund—is working to improve outcomes for people affected by this rare and complex cancer.
@ProfDMThomas, highlights the rapid progress in cancer treatment and the urgent need to ensure that patients with rare cancers like sarcoma are not left behind. @coopsfoundation A/Chairperson Colin Brading (GAICD), along with the Hardyman and Dreverman families, continues to honour the legacies of those lost to sarcoma by advancing research that can make a difference for future patients.
Read the media release: https://t.co/l2fFxNegzK
#SarcomaResearch #PrecisionOncology #MoST #CaSP #RealWorldData #Collaboration

[EHE Foundation @EHEfoundation]

There is global momentum in #EHE research and advocacy! We were honored to work with @ehe_uk and @EheItalia to amplify patients' voices in shaping global research priorities and collaborating with the European Medicines Agency (EMA).

#epithelioidhemangioendothelioma #EHEresearch

[Omico Australia @OmicoAustralia]

🌟The Australian Precision Oncology Symposium 2025 (APOS 25) is fast approaching! APOS 25 program, "The Coming of Age of Precision Oncology", designed for Australian oncology professionals—including oncologists, researchers, pathologists, and members of the life science and advocacy sectors—will showcase a pivotal moment in cancer care, as precision oncology moves from theory to transformative practice. Click here to register for in-person attendance: https://t.co/HvTWIILgqb
Click here to register for virtual attendance: https://t.co/FQ23VYrQ99 #APOS25Sponsor #Omico #APOS25 #AustralianPrecisionOncologySymposium2025 #PrecisionOncology #CancerMeetsItsMatch

[Owkin @OwkinScience]

We’re excited to share our latest work in collaboration with @sanofi, published in iScience, demonstrating how deep learning models can predict YAP1/TEAD activity—key drivers of cancer progression—directly from routine H&E-stained histology slides.

🤖 Our models successfully predict YAP1/TEAD activity, validated across 7 independent cohorts.
🔍 Tumor necrosis, immune infiltration, and poorly differentiated tumor cells were linked to dysfunctional Hippo signaling.
💡 This approach offers a reproducible, cost-effective alternative to RNA-seq for identifying patients with dysregulated Hippo signaling - integrating AI into clinical workflows.

Why does this matter? Identifying patients with abnormal YAP1/TEAD activity could enhance the impact of emerging TEAD inhibitors, setting the stage for more effective and personalized cancer therapies.

Read the full study in iScience here: https://t.co/85pP1f5yKD

#AI #PrecisionOncology #HippoPathway #TEADInhibitors

[Cristiane D Bergerot, PhD, FASCO @crisbergerot]

Rare cancers often lack research on HRQOL, leaving patients with unmet needs

Our review @Cancers_MDPI of 464 studies shows progress in HRQOL assessment but highlights gaps in tools for many cancer types @csimoes96 @Winette_vdGraaf @OlgaHusson @EORTC_QLG

https://t.co/8I5Tp4X2la

[Omico Australia @OmicoAustralia]

We are pleased to announce our upcoming Australian Precision Oncology Symposium 2025 (APOS 25)!
MEETING DETAILS
DAY 1: Friday 7 March 2025 | 1.00pm - 5.30pm. Symposium Dinner from 5.45pm
DAY 2: Saturday 8 March 2025 | 9.00am - 2.30pm
Click here to register for in-person attendance: https://t.co/HvTWIILgqb
Click here to register for virtual attendance: https://t.co/FQ23VYrQ99
#Omico #APOS25 #AustralianPrecisionOncologySymposium2025 #PrecisionOncology #CancerMeetsItsMatch #ComprehensiveGenomicProfiling

[bioRxiv Cancer Bio @biorxiv_cancer]

Development of a pipeline to evaluate YAP-TEAD inhibitor potential - direct TEAD inhibition represses cancerous growth in a ... https://t.co/sYgjwH8AEL #biorxiv_cancer

[Anirban Maitra @Aiims1742]

And right on cue!
Preprint from @genentech on a new class of TEAD small molecule inhibitors that act via distinct mechanism, by promoting the repressive TEAD-VGLL4 interaction
TEAD-targeting small molecules induce a cofactor switch to regulate the Hippo pathway.
https://t.co/ZxWNMzGlQb

[Alessandro Gronchi @alegronchi]

@Andrea_Vanzulli presenting a proposal for modified RECIST criteria - the RESCOR criteria - to assess Hepithelioid Hemangioendothelioma response to therapies and clinical course! Very nice and clear presentation. Well done Andrea! We are so lucky to have you! @IstTumori

[EHE Foundation @EHEfoundation]

Available in a patient's version (English and Italian) and a physician's version (English), the EHE Consensus Paper is a foundational resources for treating and managing EHE.

https://t.co/DdHC1nE6fn

#EHE #epithelioidhemangioendothelioma #rarecancer #sarcoma #raredisease

[EHE Foundation @EHEfoundation]

Read “Current Model Systems for Investigating Epithelioid Haemangioendothelioma,” published by Dr. Valorie Kouskoff et. al., at https://t.co/T0eNKhcKVS

#fightEHE #EHE #epithelioidhemangioendothelioma #rarecancer #fundresearch #EHEfoundation #justlive #EHEresearch

[Therapeutic Advances in Medical Oncology @TAMedOncol]

A new framework proposes criteria for extending biomarker-targeted therapies from common to rare cancers sharing the same biomarker. This approach aims to improve transparency in clinical decisions. Read more: https://t.co/oNqBwl56eh

#Oncology #CancerResearch